A Phase II Study of Sunitinib in Patients With Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma With at Least One Prior Line of Platinum-Based Systemic Chemotherapy

Trial Profile

A Phase II Study of Sunitinib in Patients With Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma With at Least One Prior Line of Platinum-Based Systemic Chemotherapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 May 2017

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Malignant thymoma; Thymoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Apr 2016 Status changed from recruiting to active, no longer recruiting.
    • 08 Mar 2016 Planned primary completion date changed from 1 Apr 2015 to 1 Apr 2018, according to ClinicalTrials.gov record.
    • 28 May 2015 Data from 74 patients across this and 3 other trials (see CT profiles 29397, 48385 and 54727) were presented at the 2015 American Society of Clinical Oncology annual meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top